Valneva ( ($VALN) ) just unveiled an update. On July 11, 2025, Valneva announced that the European Medicines Agency (EMA) lifted the temporary ...

The European Union’s health regulator has lifted the temporary restriction on the use of French drugmaker Valneva’s ...

EMA lifts suspension on Valneva's chikungunya vaccine for older adults, emphasizing its importance in high-risk situations.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 ...

Chikungunya virus disease, a debilitating mosquito-borne (Aedes spp) illness caused by an alphavirus, chikungunya virus, is usually endemic in regions with tropical climates.1 Since the beginning of ...

At its July meeting, the European Medicines Agency’s pharmacovigilance committee (PRAC) completed its review of French ...

Our data show 5.6 billion people now live in regions where Aedes mosquitoes can transmit chikungunya, and 2025 outbreaks in Réunion, Kenya, Madagascar, and ...

Under the agreed terms, CSL Seqirus will start commercializing Valneva’s single-dose chikungunya vaccine IXCHIQ ® from July 2025, and Valneva’s Japanese Encephalitis vaccine IXIARO ® and ...

Under the agreed terms, CSL Seqirus will start commercializing Valneva’s single-dose chikungunya vaccine IXCHIQ ® from July 2025, and Valneva’s Japanese Encephalitis vaccine IXIARO ® and cholera/ETEC ...

The EMA has lifted restrictions on the chikungunya vaccine in people 65 and older, while warning that it should be used only when there is significant risk of infection.

Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine ...